A Phase 2 Study of IkT-148009 in Untreated Parkinson's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Aug 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Sep 2024.
17 Jun 2024 According to an Inhibikase Therapeutics media release, the company has completed enrollment in the Phase 2 201 trial and expects to report trial results in the fourth quarter of 2024.
05 Jun 2024 According to an Inhibikase therapeutics media release, the trial has reached 94 percent enrollment and company anticipate enrolling the last patient in mid-June. The Company anticipates that the last patient will complete the 12-week treatment period before the close of the third quarter of 2024. The Company expects to report biomarker and outcome data to support the pursuit of an End of Phase 2 and Phase 3 protocol discussion with the FDA by the end of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com